Taken together, these data are suggestive of defective tumour immune surveillance in CDH17 ‘high’ versus ‘low methylation’ status stage II CC tumours, despite evidence by RNAseq of expression of IFN-γ and CXCL10 (top gene in the IFN beta signature, by GSEA). Here, CXCL10 is linked to neoplasm.